Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
BMO Capital Remains Bullish on Valeant Pharma (VRX) Following Announced Acquisition of 'Female Viagra' Maker Sprout Pharma
August 20, 2015 11:29 AM UTCBMO Capital reiterated an Outperform rating and $285 price target on Valeant Pharmaceuticals (NYSE: VRX) following the announced acquisition on Sprout Pharmaceuticals. Sprout recently received FDA approval for Addyi (filbanserin) , a non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD), on August 18th. Valeant will pay ~$1 billion... More
